[go: up one dir, main page]

LT2002035A - Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives - Google Patents

Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Info

Publication number
LT2002035A
LT2002035A LT2002035A LT2002035A LT2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A
Authority
LT
Lithuania
Prior art keywords
mesoprogestins
female
progesterone receptor
component
receptor modulators
Prior art date
Application number
LT2002035A
Other languages
Lithuanian (lt)
Other versions
LT5001B (en
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of LT2002035A publication Critical patent/LT2002035A/en
Publication of LT5001B publication Critical patent/LT5001B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of mesoprogestins for the production of a pharmaceutical for female contraception, to the pharmaceutical preparation for female contraception administering effective amounts of a mesoprogestin in a female desiring contraception. Optionally the mesoprogestin can be used in combination with an estrogen. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.
LT2002035A 1999-08-31 2002-03-26 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives LT5001B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
LT2002035A true LT2002035A (en) 2002-10-25
LT5001B LT5001B (en) 2003-03-25

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002035A LT5001B (en) 1999-08-31 2002-03-26 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Country Status (28)

Country Link
EP (1) EP1605949A2 (en)
JP (1) JP2003511399A (en)
KR (1) KR20020038745A (en)
CN (1) CN1384748A (en)
AR (1) AR025455A1 (en)
AU (1) AU781835B2 (en)
BG (1) BG106441A (en)
BR (1) BR0013711A (en)
CA (1) CA2383650A1 (en)
CO (1) CO5190694A1 (en)
CZ (1) CZ2002707A3 (en)
EA (1) EA006805B1 (en)
EE (1) EE200200103A (en)
HR (1) HRP20020265A2 (en)
HU (1) HUP0202515A3 (en)
IL (1) IL148415A0 (en)
LT (1) LT5001B (en)
LV (1) LV12940B (en)
MX (1) MXPA02002186A (en)
NO (1) NO20020998L (en)
NZ (1) NZ517470A (en)
PE (1) PE20010579A1 (en)
PL (1) PL353994A1 (en)
SI (1) SI20853A (en)
SK (1) SK2982002A3 (en)
UA (1) UA77150C2 (en)
WO (1) WO2001026603A2 (en)
YU (1) YU13902A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (en) 2002-08-02 2004-02-19 Schering Ag New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders
ATE338763T1 (en) * 2002-08-02 2006-09-15 Schering Ag PROGESTERONE RECEPTOR MODULATORS WITH INCREASED ANTIGONADOTROTIC ACTIVITY FOR FEMALE FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY
JP2006525358A (en) * 2003-05-02 2006-11-09 ドゥラメド ファーマシューティカルズ， インコーポレイテッド Hormonal therapy using long-term contraceptive regimen
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
AU2005269938A1 (en) * 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
ME02548B (en) 2009-04-14 2017-02-20 Hra Pharma Lab PROCEDURE FOR CONSIDERABLY CONTRACEPTION
CN110548034A (en) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 Pregnancy-blocking medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (en) 1936-11-20 1940-11-27 Chemische Ind Ges Process for the preparation of compounds of the estradiol type which are esterified in the 3-position
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (en) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT
ATE209919T1 (en) * 1987-09-24 2001-12-15 Jencap Res Ltd CONTRACEPT PACKS CONTAINING ESTROGEN AND PROGESTIN
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (en) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds
DE4332283A1 (en) 1993-09-20 1995-04-13 Jenapharm Gmbh Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds
DE4447715C2 (en) 1994-08-09 1998-02-05 Jenapharm Gmbh Oestrogen compsn contg. 3-sulphamoyl:oxy-oestratriene cpd.
DE4429397C2 (en) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
EP0787002B1 (en) * 1994-10-24 2006-12-13 Schering Aktiengesellschaft Competitive progesterone antagonists for regulating female fertility as required
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
CA2255863A1 (en) * 1996-06-25 1997-12-31 Akzo Nobel Nv Progestogen-anti-progestogen regimens
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
HK1043788A1 (en) * 1999-05-04 2002-09-27 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
PL353994A1 (en) 2003-12-15
CO5190694A1 (en) 2002-08-29
WO2001026603A2 (en) 2001-04-19
EE200200103A (en) 2003-04-15
EA200200284A1 (en) 2002-10-31
AR025455A1 (en) 2002-11-27
NZ517470A (en) 2004-03-26
PE20010579A1 (en) 2001-06-04
SI20853A (en) 2002-10-31
UA77150C2 (en) 2006-11-15
CZ2002707A3 (en) 2002-11-13
KR20020038745A (en) 2002-05-23
LT5001B (en) 2003-03-25
NO20020998L (en) 2002-03-14
BR0013711A (en) 2002-05-07
NO20020998D0 (en) 2002-02-28
EA006805B1 (en) 2006-04-28
HRP20020265A2 (en) 2004-02-29
SK2982002A3 (en) 2002-07-02
AU3215001A (en) 2001-04-23
JP2003511399A (en) 2003-03-25
CA2383650A1 (en) 2001-04-19
HUP0202515A3 (en) 2004-06-28
HUP0202515A2 (en) 2002-12-28
EP1605949A2 (en) 2005-12-21
MXPA02002186A (en) 2002-09-02
WO2001026603A3 (en) 2002-01-17
BG106441A (en) 2002-09-30
CN1384748A (en) 2002-12-11
AU781835B2 (en) 2005-06-16
IL148415A0 (en) 2002-09-12
YU13902A (en) 2006-01-16
LV12940B (en) 2003-06-20

Similar Documents

Publication Publication Date Title
WO1995011013A3 (en) Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
HUP0103345A3 (en) Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions
WO2004110408A3 (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
PT836506E (en) TRANSDERMAL PENSION FOR ADMINISTRATION OF 17-DECACEACY NORGESTIMATE SO OR IN COMBINATION WITH A ESTROGEN
WO2002047693A3 (en) Steroid hormone products comprising a stabilizing agent in non-crystalline form
CA2188907A1 (en) Combination compound for contraception based on natural estrogen
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
WO2000042942A3 (en) Buccal drug delivery system for use in male contraception
LT2002035A (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
WO2000074649A3 (en) Ophthalmic histamine compositions and uses thereof
YU14002A (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
HUP0203721A2 (en) Novel hormonal composition and the use thereof
WO1999020223A3 (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
EA200601089A1 (en) TRANSDERMAL DELIVERY OF HORMONES WITHOUT THE NEED TO USE AGENTS, STRENGTHENING PENETRATION
WO2001034126A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
MXPA01011296A (en) Contraceptive compositions containing indoline derivatives and progestational agents.
WO2003099322A3 (en) Il-11 derivatives and therapeutic uses thereof
WO1996028154A3 (en) Use of anti-oestrogens as male contraceptives
TW200640468A (en) Pharmaceutical product for oral contraception
Robb-Nicholson By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: SCHERING AKTIENGESELLSCHAFT, DE

Effective date: 20030513

MM9A Lapsed patents

Effective date: 20080831